Wednesday, July 29, 2009

Yesterday, we followed up on our application that was sent to Bayer on Friday, July 24th. We were told it should take only a couple of days and that things looked good. Every day is another waiting game.


This would be Amiee's 'on week' for chemo but the taxotere and gemzar she's been on for the past two months has stopped working. Like all the others. We saw some initial results after a couple of treatments. The tumor was breaking up. Unlike most cancers, hers is in her mouth so we can watch it grow and shrink....and grow. No testing required. No surprises. After the first couple of treatments it was growing again. Our hopes are with Nexavar now, which is primarily used for kidney cancer but we are told it has some affect on sarcomas. From what we've been told, her tumor is too large to see a positive response from the drug, but we are out of options.

We'll keep you updated as we receive new information. If you have any information to share regarding nexavar, soft tissue sarcomas, or the "compassionate use" of drugs by pharmaceutical companies, we'd love to hear about it.

Best wishes and smiles

NEXAVAR INFORMATION

Because sacomas generally have a poor prognosis, Nexavar can sometimes be requested for use in sarcoma.

Sarcomas can be divided into roughly two groups: chemo responsive varieties, such as Kaposi, soft tissue sarcoma, Ewings etc; poorly responsive varieties, such as chodrosarcoma and others.

Two Sorafenib (Nexavar) Clinical Trials are Currently Recruiting Sarcoma Patients in Different Locations Across the USA.

1. Phase II Study of Sorafenib in Patients With Advanced Soft Tissue Sarcomas

2. Sorafenib in Treating Patients With Soft Tissue Sarcomas

There is also a Kaposi's phase I trial and trials for GIST and other sarcoma types. Nexavar is an investigational treatment currently for sarcoma.

http://www.cancer.gov/clinicaltrials/NCI-06-C-0083

B . Kasper , T . Gil , V . D’Hondt , M . Gebhart , A . Awada Novel treatment strategies for soft tissue sarcoma Critical Reviews in Oncology/Hematology , Volume 62 , Issue 1 , Pages 9 - 15, 2007

0 Comments:

Post a Comment